241 related articles for article (PubMed ID: 36094605)
21. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
22. Tectal Low-Grade Glioma with H3 K27M Mutation.
Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
[TBL] [Abstract][Full Text] [Related]
23. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
[TBL] [Abstract][Full Text] [Related]
24. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
25. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient.
Fujioka Y; Hata N; Hatae R; Suzuki SO; Sangatsuda Y; Nakahara Y; Mizoguchi M; Iihara K
Neuropathology; 2020 Feb; 40(1):99-103. PubMed ID: 31762138
[TBL] [Abstract][Full Text] [Related]
26. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy in H3K27M diffuse midline glioma.
Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
[TBL] [Abstract][Full Text] [Related]
28. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
[TBL] [Abstract][Full Text] [Related]
29. [Pediatric-Type Diffuse High-Grade Gliomas].
Natsumeda M
No Shinkei Geka; 2023 Sep; 51(5):876-883. PubMed ID: 37743339
[TBL] [Abstract][Full Text] [Related]
30. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
31. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Low JT; Wang SH; B Peters K
CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
[TBL] [Abstract][Full Text] [Related]
32. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
33. Disseminated diffuse midline glioma associated with poorly differentiated orbital lesion and metastases in an 8-year-old girl: case report and literature review.
Silva MA; Mirchia K; Chamyan G; Maher O; Wang S; Niazi T
Childs Nerv Syst; 2022 Oct; 38(10):2005-2010. PubMed ID: 35460354
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
Chen H; Hu W; He H; Yang Y; Wen G; Lv X
Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
[TBL] [Abstract][Full Text] [Related]
35. A rare case of adult diffuse midline glioma with H3 K27M mutant in the prepontine cistern.
Chen X; Zhong L; Lin J; Yu J
J Int Med Res; 2021 Jan; 49(1):300060520981266. PubMed ID: 33435779
[TBL] [Abstract][Full Text] [Related]
36. Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review.
Onishi S; Ohba S; Kuraoka K; Kurashige T; Sugiyama K; Yamasaki F
Neurocirugia (Astur : Engl Ed); 2022; 33(6):356-360. PubMed ID: 36333093
[TBL] [Abstract][Full Text] [Related]
37. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
[TBL] [Abstract][Full Text] [Related]
38. A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report.
Babarczy K; Reisz Z; Szabo E; Rajda C; Vecsei L; Bodi I; Klivenyi P; Hortobagyi T; Szalardy L
Folia Neuropathol; 2020; 58(4):377-385. PubMed ID: 33480242
[TBL] [Abstract][Full Text] [Related]
39. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract][Full Text] [Related]
40. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]